Changing Market Dynamics Demand New, Innovative Model to Increase Speed to Therapy and Better Serve Patients
In a new 60-minute virtual panel, “Next Gen Commercial Models in Oncology,” PharmaVOICE Editor Taren Grom sat down with industry leaders to discuss how changing market dynamics and a rich pipeline in oncology are creating a need for next gen commercial models.
Watch the video below to learn how to leverage an innovative, agile and “fit-to-scale” model to accelerate speed to market, manage costs and lower risk.
Companies spend >$125MM over three years leading up to launch, and 66% of drugs still don’t meet launch expectations. This looming risk, echoed by general industry pressures, leaves developers and investors alike looking for more advanced commercialization options that effectively maximize their pipelines. Contact us to discuss how your asset can immediately benefit from EVERSANA COMPLETE Commercialization.
EVERSANA employs a team of over 2500 professionals across 27 locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…